News & Articles

Workflow is quick, simple and scalable for high-throughput antibody detection with high PPA sensitivity and NPA specificity

The real-time PCR workflow has a capacity of up to 6,000 tests per day per system, and demonstrated 100% agreement with authorized nasopharyngeal assays

Second manufacturing expansion will help meet global demand for research, clinical and GMP grade raw materials as well as research and clinical-grade APIs to include mRNA, self-amplifying RNA and plasmid DNA

Hear how one trailblazing lab at the Broad Institute of MIT and Harvard is using automated sample tracking to monitor pandemics such as Ebola Virus Disease and COVID-19

Supports cross-functional teams of chemists and biologists developing non-natural, chemically modified therapeutics for drug discovery

Researchers at the University of Bern have now discovered which genes play an important role in the response to radiation therapy

A Cambridge-developed vaccine candidate against SARS-CoV-2 could begin clinical trials in the UK as early as autumn, thanks to a £1.9million award from the UK government

The overall goal is to continue to detect and discover critical components in the overall cellular response to COVID-19

QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing, whereas QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research

Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season

The new kits are based on the technology of the PerkinElmer New Coronavirus Nucleic Acid Detection Kit

A Presidential award-winning laboratory has developed a new technology to address one of the most pressing challenges in nanomedicine

Watch this on-demand webinar to gain insight on how advanced flow cytometry and live-cell analysis can facilitate faster drug development

The kits aim to detect traces of SARS-CoV-2 virus on surfaces such as plastics, ceramics and stainless steel

Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S.

It is the first and only approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology

The AccuPlex SARS-CoV-2 molecular controls kit is designed to measure day-to-day assay performance and contains positive materials

The test outperforms other molecular tests with a low detection limit of 15 GEC/reaction (250 GEC/ml of sample) and a robust control system

The consortium aims to determine the dynamics, function and potential for therapeutic intervention of the RNA and protein structures of SARS-CoV-2

IgM assay has 95.51% positive predictive value even when disease incidence is only 3%

The new assays are designed to enable turnaround times for next-generation sequencing results of less than 24 hours